SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Andreasson F.) "

Search: WFRF:(Andreasson F.)

  • Result 1-10 of 118
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Elhai, M, et al. (author)
  • Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
  • 2019
  • In: Annals of the rheumatic diseases. - : BMJ. - 1468-2060 .- 0003-4967. ; 78:7, s. 979-987
  • Journal article (peer-reviewed)abstract
    • To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical practice.MethodsWe performed a prospective study including patients with SSc from the European Scleroderma Trials and Research (EUSTAR) network treated with rituximab and matched with untreated patients with SSc. The main outcomes measures were adverse events, skin fibrosis improvement, lung fibrosis worsening and steroids use among propensity score-matched patients treated or not with rituximab.Results254 patients were treated with rituximab, in 58% for lung and in 32% for skin involvement. After a median follow-up of 2 years, about 70% of the patients had no side effect. Comparison of treated patients with 9575 propensity-score matched patients showed that patients treated with rituximab were more likely to have skin fibrosis improvement (22.7 vs 14.03 events per 100 person-years; OR: 2.79 [1.47–5.32]; p=0.002). Treated patients did not have significantly different rates of decrease in forced vital capacity (FVC)>10% (OR: 1.03 [0.55–1.94]; p=0.93) nor in carbon monoxide diffusing capacity (DLCO) decrease. Patients having received rituximab were more prone to stop or decrease steroids (OR: 2.34 [1.56–3.53], p<0.0001). Patients treated concomitantly with mycophenolate mofetil had a trend for better outcomes as compared with patients receiving rituximab alone (delta FVC: 5.22 [0.83–9.62]; p=0.019 as compared with controls vs 3 [0.66–5.35]; p=0.012).ConclusionRituximab use was associated with a good safety profile in this large SSc-cohort. Significant change was observed on skin fibrosis, but not on lung. However, the limitation is the observational design. The potential stabilisation of lung fibrosis by rituximab has to be addressed by a randomised trial.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  • Henstrom, M., et al. (author)
  • Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome
  • 2018
  • In: Gut. - : BMJ. - 0017-5749 .- 1468-3288. ; 67:2, s. 263-270
  • Journal article (peer-reviewed)abstract
    • Objective IBS is a common gut disorder of uncertain pathogenesis. Among other factors, genetics and certain foods are proposed to contribute. Congenital sucraseisomaltase deficiency (CSID) is a rare genetic form of disaccharide malabsorption characterised by diarrhoea, abdominal pain and bloating, which are features common to IBS. We tested sucrase-isomaltase (SI) gene variants for their potential relevance in IBS. Design We sequenced SI exons in seven familial cases, and screened four CSID mutations (p.Val557Gly, p. Gly1073Asp, p.Arg1124Ter and p.Phe1745Cys) and a common SI coding polymorphism (p.Val15Phe) in a multicentre cohort of 1887 cases and controls. We studied the effect of the 15Val to 15Phe substitution on SI function in vitro. We analysed p.Val15Phe genotype in relation to IBS status, stool frequency and faecal microbiota composition in 250 individuals from the general population. Results CSID mutations were more common in patients than asymptomatic controls (p=0.074; OR=1.84) and Exome Aggregation Consortium reference sequenced individuals (p=0.020; OR=1.57). 15Phe was detected in 6/7 sequenced familial cases, and increased IBS risk in case-control and population-based cohorts, with best evidence for diarrhoea phenotypes (combined p=0.00012; OR=1.36). In the population-based sample, 15Phe allele dosage correlated with stool frequency (p=0.026) and Parabacteroides faecal microbiota abundance (p=0.0024). The SI protein with 15Phe exhibited 35% reduced enzymatic activity in vitro compared with 15Val (p<0.05). Conclusions SI gene variants coding for disaccharidases with defective or reduced enzymatic activity predispose to IBS. This may help the identification of individuals at risk, and contribute to personalising treatment options in a subset of patients.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-10 of 118
Type of publication
journal article (98)
conference paper (16)
reports (3)
research review (1)
Type of content
peer-reviewed (94)
other academic/artistic (24)
Author/Editor
Hajdu, Janos (19)
Zetterberg, Henrik, ... (15)
Andreasson, Jakob (15)
Blennow, Kaj, 1958 (14)
Andreasson, Ulf, 196 ... (14)
Timneanu, Nicusor (12)
show more...
Maia, Filipe R. N. C ... (11)
Samuelsson, J (10)
Andreasson, B (10)
Andreasson, Anna (10)
Andreasson, A (10)
Barty, Anton (10)
Seibert, M Marvin (9)
Svenda, Martin (9)
Ekeberg, Tomas (8)
Andreasson, Jakob, 1 ... (8)
Andreasson, S (7)
Zweegman, S (7)
Harrison, C (7)
Bielecki, Johan (7)
Chapman, Henry N. (7)
Bostedt, Christoph (7)
Johansson, P. (6)
Agreus, L (6)
Birgegård, Gunnar (6)
Andréasson, Sten (6)
Lindberg, G (6)
D'Amato, M (6)
Agréus, Lars (6)
Cervantes, F (6)
Besses, C (6)
Andersson, Inger (6)
Nettelblad, Carl (6)
Sun, X. (5)
Xu, Z. (5)
Lehmann, T. (5)
Zhang, P (5)
Xu, J (5)
Ferrari, M (5)
Reiter, A (5)
D'Amato, Mauro (5)
Chapman, H. N. (5)
Bostedt, C. (5)
Kirian, Richard A. (5)
DePonte, Daniel P. (5)
Liang, Mengning (5)
Stellato, Francesco (5)
Daurer, Benedikt J. (5)
Loh, N. Duane (5)
Andréasson, F. (5)
show less...
University
Karolinska Institutet (44)
Uppsala University (33)
University of Gothenburg (24)
Lund University (19)
Chalmers University of Technology (17)
Royal Institute of Technology (10)
show more...
Stockholm University (9)
Linköping University (9)
Swedish University of Agricultural Sciences (5)
Umeå University (4)
Örebro University (4)
Halmstad University (2)
Linnaeus University (2)
Luleå University of Technology (1)
Mid Sweden University (1)
show less...
Language
English (118)
Research subject (UKÄ/SCB)
Medical and Health Sciences (54)
Natural sciences (38)
Engineering and Technology (5)
Agricultural Sciences (3)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view